LI
FPRX

Leap Investments’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Leap Investments’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,000
Closed -$30K – 641
2020
Q1 		$30K Sell
13,000
-16,348
-56% -$69.4K 0.04% 345
2019
Q4 		$135K Buy
+29,348
New +$116K 0.06% 359

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Leap Investments's FPRX Position: Q2 2020 in Review

Leap Investments sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2020, closing a stake of 13,000 shares — an estimated $30K sold.

Leap Investments first reported a position in FPRX in Q4 2019 and held it in 2 quarters. The position peaked at $135K in Q4 2019. 98 funds tracked by Wall St. Rank hold FPRX as of Q2 2020.

  • Leap Investments reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2020 after selling out during the quarter.
  • Leap Investments sold 13,000 Five Prime Therapeutics, Inc. shares in Q2 2020, an estimated $30K.
  • Leap Investments first reported a position in Five Prime Therapeutics, Inc. in Q4 2019 and held it in 2 quarters.
  • Leap Investments's Five Prime Therapeutics, Inc. position peaked at $135K in Q4 2019.
  • 98 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2020.

Based on Leap Investments's 13F filing for Q2 2020, filed 3 Aug 2020.